Form 4: Regeneron Director George L. Sing Reports Stock Transactions

Director George L. Sing reports exercising stock options and selling shares of Regeneron Pharmaceuticals on February 26, 2024.

Summary

• On February 26, 2024, George L. Sing, a director of Regeneron Pharmaceuticals, exercised non-qualified stock options to acquire 1,000 shares of common stock at a price of $413.33 per share.
• Simultaneously, Mr. Sing sold 500 shares of Regeneron common stock at $990 per share and another 500 shares at $995 per share.
• Following these transactions, Mr. Sing directly owns 26,349 shares of Regeneron common stock.
• He also indirectly owns 750 shares through his spouse, 400 shares through his spouse/custody of his son, and 1,000 shares through a trust for his son.
• Mr. Sing continues to hold 5,338 derivative securities in the form of non-qualified stock options.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when corporate insiders, like directors, buy or sell their company's stock. It provides transparency to the market regarding the transactions of those with privileged information.

Key Dates